A leading provider of
innovative DNA Screening solutions
IGH/MYEOV Translocation, Dual Fusion LPH 045
The most common translocation in Multiple Myeloma is the t(11;14)(q13;q32) which accounts for 15-20% of cases that were identified by FISH. These translocations lead to overexpression of Cyclin D1 in about 25% of cases. The breakpoints in Multiple Myeloma cases are dispersed within a 360Kb region between CCND1 and MYEOV genes. MYEOV is a putative oncogene and it's thought to be activated in the translocation by it becoming closely associated with IGH enhancers, which results in a poor prognosis for the patient.
IGH/MYEOV Translocation, Dual Fusion
Cat. No. LPH 045-S (5 tests)
Cat. No. LPH 045 (10 tests)
- MM
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK